vaccin
key
highli
costeffect
intervent
fight
infecti
diseas
led
erad
smallpox
diseas
expect
erad
short
term
includ
poliomyel
despit
outstand
benefit
deriv
vaccin
mani
obstacl
develop
deploy
novel
improv
vaccin
remain
sheerin
et
al
current
use
vaccin
base
whole
microorgan
virus
attenu
kill
form
although
vaccin
possess
high
immunogen
efficaci
aspect
could
improv
better
reactogen
reduct
risk
develop
diseas
popul
group
eg
immunocompromis
individu
develop
safer
vaccin
achiev
gener
subunit
vaccin
formul
antigen
compon
pathogen
one
challeng
address
regard
poor
immunogen
individu
antigen
frequent
issu
due
low
molecular
complex
absenc
pamp
formul
stimul
innat
immun
mechan
subsequ
trigger
induct
adapt
immun
respons
therefor
inclus
adjuv
subunit
vaccin
formul
need
achiev
induct
strong
protect
immun
respons
bastola
et
al
molecular
tool
knowledg
viral
structur
allow
gener
novel
biomed
applic
gene
therapi
vector
howev
highlight
applic
sens
product
viruslik
particl
vlp
multimer
protein
complex
resembl
viru
lack
genet
materi
thu
unabl
replic
caus
diseas
retain
immunogen
activ
sinc
mimic
viru
shape
size
surfac
antigen
determin
high
immunogen
vlp
could
avoid
need
accessori
adjuv
charlton
hume
et
al
fact
vlp
use
immunostimul
abl
mediat
protect
diseas
without
use
specif
antigen
attribut
activ
innat
immun
system
mechan
wiley
et
al
interact
vlp
innat
immun
system
major
import
induct
adapt
immun
respons
innat
immun
cell
recogn
interact
vlp
basi
two
major
characterist
size
surfac
geometri
mohsen
et
al
therefor
vlp
highli
attract
target
vaccin
develop
term
safeti
efficaci
compar
vaccin
base
attenu
inactiv
virus
vlp
structur
compris
one
structur
protein
arrang
one
sever
layer
case
particl
envelop
lipid
membran
zhao
et
al
mani
case
target
antigen
conform
vlp
structur
thu
vaccin
easili
produc
purifi
case
vlp
adopt
carri
unrel
antigen
vaccin
target
pathogen
decad
develop
vlpsbase
vaccin
sever
patholog
led
great
advanc
biomedicin
result
commerci
vaccin
fight
human
diseas
hepat
b
e
virus
human
papillomaviru
donaldson
et
al
park
moreov
sever
vlpsbase
vaccin
candid
current
clinic
evalu
scheme
compris
parenter
administr
includ
vaccin
noroviru
lerouxroel
et
al
malaria
chichest
et
al
influenza
pillet
et
al
present
chapter
rather
focus
vaccin
evalu
mucos
immun
scheme
sinc
simpl
safe
immun
mode
could
also
lead
substanti
save
cost
vaccin
campaign
sinc
train
personnel
steril
devic
requir
fact
formul
oral
nasal
vaccin
base
dri
formul
may
avoid
use
cold
chain
distribut
practic
way
expand
vaccin
coverag
develop
countri
low
cost
moreov
nasal
oral
immun
allow
induc
attract
immun
respons
instanc
nasal
rout
shown
superior
parenter
administr
vlpsbase
vaccin
elicit
iga
distal
mucos
site
critic
protect
port
entri
pathogen
oral
rout
optim
scheme
induc
iga
intestin
respons
protect
intestin
pathogen
also
provid
system
humor
respons
nardellihaeflig
et
al
buonaguro
et
al
current
vaccin
approv
human
use
base
mucos
immun
scheme
intranas
influenza
vaccin
approv
clinic
use
fda
base
live
attenu
virus
treanor
et
al
nichol
et
al
belsh
et
al
formul
deserv
improv
instanc
replac
attenu
viru
inactiv
viru
vlp
could
reduc
risk
immunocompromis
individu
develop
diseas
tamura
et
al
case
oral
vaccin
oral
polio
vaccin
base
attenu
viru
use
decad
contribut
declin
poliomyel
case
nonetheless
emerg
poliomyel
case
caus
vaccinederiv
strain
report
bandyopadhyay
et
al
oral
vaccin
cholera
anoth
exampl
mucos
vaccin
approv
human
use
base
whole
kill
bacterium
plu
recombin
cholera
toxin
b
subunit
bi
et
al
gener
vaccin
base
vlp
first
compris
express
structur
protein
serv
scaffold
assembl
vlp
process
occur
vivo
vitro
express
vlpform
protein
perform
genet
engin
host
includ
bacteria
yeast
insect
cell
plant
cell
mammalian
cell
choic
host
basic
depend
cost
requir
term
posttransl
modif
fuenmayor
et
al
instanc
glycosyl
may
impact
vlp
immunogen
report
mannosyl
enhanc
uptak
vlp
antigen
present
cell
albarwani
et
al
case
vlp
resembl
envelop
viru
typic
requir
use
mammalian
cell
line
possess
cellular
machineri
properli
produc
particl
vlp
resembl
phage
natur
effici
express
recombin
e
coli
lowcost
system
compar
insect
mammalian
cell
plant
also
use
lowcost
express
platform
effici
produc
vlp
deriv
plant
virus
vlp
resembl
mammalian
virus
even
envelop
virus
pillet
et
al
vlp
exploit
vaccin
sever
way
repres
fig
vlp
assembl
vivo
resembl
viral
assembl
also
assembl
vitro
either
spontan
induc
chang
ph
salin
purif
vlpform
protein
mani
case
vlpform
protein
vaccin
antigen
thu
vlpsbase
vaccin
obtain
straightforward
manner
case
vlp
specif
viru
use
scaffold
display
unrel
antigen
target
pathogen
case
basic
two
methodolog
address
object
genet
fusion
chemic
coupl
former
consist
design
chimer
vlp
compris
vlpform
protein
unrel
antigen
site
insert
foreign
protein
sequenc
select
properli
avoid
alter
assembl
properti
scaffold
protein
allow
display
foreign
antigen
case
limit
length
foreign
protein
exist
consid
vlp
design
fusion
gene
gener
express
proper
host
result
vlp
gener
display
unrel
antigen
surfac
way
chimer
vlp
serv
carrier
unrel
epitop
offer
possibl
produc
multival
vaccin
includ
sever
epitop
chimer
protein
wu
et
al
kingston
et
al
anoth
strategi
consist
chemic
coupl
peptid
surfac
vlp
methodolog
wide
appli
case
phagederiv
vlp
phage
protein
effici
produc
recombin
bacteria
low
rapid
process
instanc
vlp
deriv
bacteriophag
use
carrier
unrel
antigen
synthet
peptid
display
repetit
fashion
surfac
coupl
peptid
vlp
typic
base
use
heterobifunct
linker
use
twostep
conjug
scheme
anoth
report
approach
consist
substitut
methionin
residu
vlp
analogu
contain
termin
azid
azidohomoalanin
aha
alkyn
homoproparglyglycin
hpg
group
azid
alkyn
function
small
molecul
protein
subsequ
coupl
vlp
use
click
chemistri
strabl
et
al
obtain
vlp
highli
immunogen
mice
lechner
et
al
human
maurer
et
al
interestingli
sinc
rna
host
e
coli
captur
insid
vlp
assembl
serv
adjuv
act
tolllik
receptor
ligand
enhanc
vaccin
efficaci
especi
induct
antibodi
respons
forsbach
et
al
besid
antigen
peptid
vlp
use
also
carrier
carbohydr
epitop
nicotin
develop
vaccin
leishmania
infect
tobacco
depend
respect
moura
et
al
maurer
bachmann
interestingli
bessa
et
al
demonstr
differ
fig
represent
strategi
produc
vlp
use
vaccin
develop
vlpform
protein
obtain
heterolog
express
appropri
host
eg
bacteria
yeast
plant
cell
insect
cell
vlp
assembl
vivo
vitro
purifi
vlpform
protein
monomer
form
genet
modif
allow
produc
chimer
vlp
display
unrel
antigen
make
possibl
product
bi
multival
vaccin
conjug
approach
allow
coval
attach
unrel
epitop
synthet
peptid
onto
vlp
surfac
ii
efficaci
system
igg
iga
respons
follow
subcutan
versu
intranas
immun
augur
interest
potenti
develop
mucos
nanovaccin
anoth
exampl
phage
use
scaffold
gener
vlp
salmonella
typhimurium
bacteriophag
shorttail
phage
dsdna
genom
viral
capsid
compos
copi
kda
coat
protein
cp
copi
kda
scaffold
protein
sp
encapsid
within
immatur
procapsid
noninfecti
vlp
assembl
coexpress
cp
sp
result
nm
diamet
cage
heterolog
protein
includ
vlp
fuse
scaffold
domain
sp
coexpress
cp
oneil
et
al
thu
modular
avoid
possibl
alter
cp
vlp
assembl
plant
virus
also
serv
sourc
vlpsform
protein
appli
vaccin
develop
case
follow
virus
almv
cmv
cpmv
papmv
pvx
tmv
review
balk
zeltin
importantli
two
plant
virusderiv
vaccin
current
evalu
clinic
trial
malaria
vaccin
base
almv
antigen
phase
clinic
trial
http
papmv
vlp
evalu
adjuv
season
flu
trival
vaccin
http
interestingli
vlp
function
load
accessori
molecul
improv
vaccin
efficaci
instanc
vlp
load
adjuv
cpg
ligand
favor
antigen
process
innat
immun
system
fact
proven
coadministr
vlp
load
cpg
plu
vlp
display
target
antigen
result
deliveri
adjuv
antigen
apc
simplifi
vaccin
product
mohsen
et
al
anoth
approach
consist
genet
fuse
immunostimulatori
signal
vlp
instanc
hiv
vlp
contain
inductor
costimulatori
molecul
apc
show
high
immunogen
gag
franco
et
al
siv
vlp
contain
glycosylphosphatidylinositol
gpi
anchor
gmcsf
cytokin
act
adjuv
induc
higher
level
neutral
antibodi
plain
siv
vlp
skountzou
et
al
chimer
rabi
viruslik
particl
crvlp
display
either
membraneanchor
flagellin
ltb
induc
enhanc
immunogen
immunoprotect
capac
mice
dog
qi
et
al
fig
although
vlpsbase
vaccin
becom
realiti
clinic
realm
parenter
vaccin
develop
mucos
formul
progress
lower
degre
chapter
provid
gener
outlook
ongo
research
look
develop
mucos
vaccin
formul
relev
human
anim
diseas
tabl
influenza
viru
seriou
threat
global
health
lead
high
econom
burden
sinc
pathogen
mutat
continu
new
variant
evad
preexist
immun
thu
new
vaccin
requir
addit
must
produc
short
time
pandem
human
case
indic
great
need
platform
abl
result
effect
vaccin
short
time
chen
et
al
lee
et
al
explor
potenti
use
vlp
base
matrix
protein
tandem
repeat
ectodomain
deriv
human
swine
avian
avian
influenza
virus
approach
induc
broad
crossprotect
influenza
viru
strain
variant
insect
cellmad
vlp
administ
mice
dose
vlp
total
protein
protein
boost
perform
week
anim
challeng
either
aphil
aviet
viru
vlp
reduc
weight
loss
attenu
inflammatori
cytokin
cellular
infiltr
decreas
viral
load
induc
germin
center
phenotyp
b
plasma
cell
vaccin
induc
antibodi
sera
mucos
tissu
confer
effect
crossprotect
heterosubtyp
influenza
virus
balanc
respons
evid
accord
measur
tcell
role
observ
protect
effect
configur
genet
modifi
vlp
use
vaccin
product
viruslik
particl
genet
modifi
incorpor
peptid
protein
antigen
red
genet
fusion
cntermini
flexibl
loop
region
vlpform
protein
blue
accessori
adjuv
protein
sequenc
ltb
flic
also
attach
yellow
enhanc
immunogen
particl
strategi
allow
obtain
vlp
exact
placement
target
antigen
within
final
particl
defin
number
target
antigen
molecul
per
particl
patterson
et
al
report
vaccin
base
vlp
obtain
coexpress
e
coli
coat
protein
either
truncat
version
np
antigen
np
full
length
np
fuse
truncat
scaffold
sp
vlp
carri
either
np
version
administ
mice
daili
day
dose
vlp
vaccin
version
abl
induc
strong
protect
immun
respons
mice
challeng
either
influenza
virus
protect
respons
part
attribut
npspecif
lymphocyt
respons
term
humor
respons
full
length
npbase
vaccin
induc
antinp
antibodi
wherea
truncat
np
data
correl
lower
protect
rate
mice
immun
truncat
npbase
vaccin
accord
result
report
vaccin
potenti
candid
requir
accessori
adjuv
achiev
protect
anoth
vlpsbase
influenza
vaccin
candid
propos
nerom
et
al
produc
express
influenza
viru
hemagglutinin
ha
silkworm
pupa
mice
oral
immun
ha
vlp
differ
scheme
compris
two
month
interv
three
immun
interv
twodos
ip
scheme
also
employ
chicken
immun
three
time
oral
ha
titer
vlp
vlp
ha
vlp
show
posit
immunoreact
authent
antibodi
vlp
trigger
humor
respons
chicken
mice
upon
oral
immun
antibodi
elicit
upon
oral
immun
confirm
fluoresc
antibodi
analysi
western
blot
korea
habmnpv
recombin
infect
bmn
cell
challeng
experi
report
platform
advantag
would
allow
largescal
product
vaccin
rel
low
cost
sinc
use
expens
cultur
media
requir
insect
cell
cultur
avoid
ren
et
al
explor
idea
produc
influenza
vlp
decor
membraneanchor
form
e
coli
heatlabil
enterotoxin
b
subunit
protein
ltb
tolllik
receptor
ligand
flagellin
flic
accessori
mucos
adjuv
purpos
vlp
compos
viral
ha
na
protein
produc
insect
cell
fig
mice
subject
three
weekli
dose
vlp
administ
im
oral
rout
vlp
contain
ltb
flic
gener
higher
humor
cellular
immun
respons
plain
influenza
vlp
intramuscular
immun
plant
vlp
vlpsctb
vlpsflic
protect
mice
lethal
challeng
homolog
heterolog
virus
contrast
oral
immun
mice
vlpsltb
vlpsflic
confer
substanti
protect
lethal
challeng
homolog
heterolog
influenza
virus
surviv
rate
wherea
mice
immun
plain
vlp
succumb
infect
fig
mice
immun
oral
ltbor
flicvlp
show
tenfold
higher
virusspecif
igg
titer
mice
immun
plain
vlp
thu
accessori
adjuv
promis
tool
appli
develop
vaccin
pathogen
wang
et
al
use
insect
cellmad
vlp
consist
ha
protein
plu
flic
cvlp
plu
flagellin
cvlp
author
previous
prove
flic
inclus
vlp
allow
protect
mice
im
immun
challeng
heterosubtyp
strain
studi
mice
immun
twice
vlp
interv
cvlp
induc
robust
cellular
respons
enhanc
system
mucos
antibodi
respons
compar
plain
influenza
vlp
moreov
vaccin
provid
full
protect
challeng
either
homolog
heterosubtyp
virus
plain
vlp
induc
protect
upon
heterosubtyp
challeng
upon
coadministr
plain
vlp
solubl
flagellin
exhibit
moder
adjuv
effect
evidenc
enhanc
system
mucos
respons
partial
heterosubtyp
protect
anoth
vlpsbase
influenza
vaccin
report
mohsen
et
al
chimer
influenza
vlp
gener
express
glycosylphosphatidylinositol
gpi
anchor
latter
mucosaeassoci
epitheli
chemokin
bind
chemokin
receptor
involv
migrat
antibodi
secret
cell
asc
mucos
tissu
thu
exert
adjuv
effect
vaccin
evalu
mice
immun
twice
interv
ha
membranebound
solubl
cvlp
induc
enhanc
humor
respons
compar
influenza
vlp
without
influenza
vlp
co
administ
solubl
upon
challeng
cvlptreat
group
show
strong
recal
respons
reduc
viral
load
inflammatori
respons
cvlp
result
crossprotect
drift
philippin
protect
homolog
aichi
virus
fig
vaccin
base
chimer
vlp
deriv
hepat
b
viru
core
antigen
gene
hbc
report
zheng
et
al
aa
hbc
replac
long
alphahelix
lah
gene
fragment
code
aa
conserv
among
differ
influenza
strain
thu
offer
opportun
develop
broadspectrum
influenza
vaccin
e
colimad
vlp
obtain
fig
test
mice
dose
mice
immun
thrice
interv
vlp
alon
coadminist
chi
mice
n
im
oral
immun
ltbvlp
flicvlp
mockimmun
mice
use
control
group
five
week
first
immun
mice
infect
dose
ad
jlsiv
viru
dh
mice
examin
daili
day
chang
bodi
weight
c
e
g
surviv
b
f
h
chang
bodi
weight
chang
calcul
use
bodi
weight
day
viral
challeng
data
present
mean
sd
n
taken
ren
et
al
permit
number
tosan
ctb
anoth
group
receiv
vlp
ip
plu
alum
test
vlp
induc
dose
effect
humor
cellular
immun
respons
provid
complet
protect
lethal
challeng
use
homolog
viru
heterolog
viru
im
administr
provid
weak
protect
either
test
adjuv
provid
full
protect
wherea
unadjuv
vaccin
led
lower
protect
rate
vaccin
result
partial
protect
lethal
challeng
heterolog
viru
fig
immun
approach
influenza
base
vlp
describ
bessa
et
al
author
produc
vlp
deriv
phage
e
coliproduc
plain
function
influenza
viru
deriv
ectodomain
protein
humor
respons
induct
peptid
major
ctl
epitop
lymphocyt
choriomening
viru
model
ctl
epitop
latter
conjug
contain
cpg
accessori
adjuv
mice
sc
immun
plain
vlp
latter
induc
strong
igg
respons
serum
lung
iga
serum
mice
aichi
philippin
weight
loss
higher
use
endpoint
mice
euthan
accord
iacuc
guidelin
chang
bodi
weight
display
mean
repres
one
experi
surviv
differ
evalu
logrank
mantelcox
test
n
taken
mohsen
et
al
immun
induc
iga
product
lung
larg
number
germin
center
gc
well
memori
bcell
spleen
plasma
cell
bone
marrow
immun
also
provid
signific
protect
challeng
lethal
dose
influenza
viru
strain
contrast
immun
induc
rel
ineffici
cytotox
tcell
respons
result
low
number
specif
tcell
poor
effector
cell
differenti
report
support
use
phage
nasal
vaccin
product
surprisingli
sinc
public
report
addit
effort
report
appli
phage
develop
vaccin
relev
pathogen
especi
humor
respons
critic
protect
outstand
approach
oral
vaccin
recent
report
serradel
et
al
consist
produc
vlp
base
murin
leukemia
viru
mlv
capsid
protein
gag
variant
specif
surfac
protein
vsp
giardia
lamblia
surfac
antigen
influenza
viru
hemagglutinin
ha
neuraminidas
na
protein
fuse
transmembran
domain
cytoplasm
tail
g
protein
vesicular
stomat
viru
vsvg
vlp
produc
cell
oral
sc
administ
mice
four
time
interv
dose
oral
sc
immun
strategi
allow
display
vlp
surfac
ha
vsp
latter
shown
protect
vlp
degrad
activ
apc
use
vitro
assay
oral
administ
vlpsvsp
plain
vlp
express
ha
gener
robust
immun
respons
term
serum
iga
fece
bronchoalveolar
lavag
vlpsvsp
administ
parenter
show
superior
immunogen
respect
plain
vlp
induc
mucos
humor
respons
interestingli
vlpsvsp
induc
full
protect
influenza
viru
challeng
wherea
plain
vlp
author
also
challeng
mice
murin
malign
mesothelioma
cell
express
ha
observ
vlpsvsp
control
tumor
growth
almost
complet
analysi
confirm
vlpsvsp
induc
robust
tcell
respons
vitro
cytotox
tumor
cell
fig
outstand
approach
offer
promis
path
develop
oral
vaccin
requir
adjuv
ten
day
immun
vlp
mice
challeng
mouseadapt
influenza
viru
n
kaplanmei
life
surviv
curv
analysi
perform
use
logrank
mantelcox
method
curv
comparison
analysi
bodi
weight
present
percentag
initi
averag
weight
regist
day
chang
bodi
weight
evalu
week
b
c
ten
day
last
immun
mice
immun
vlp
inject
tumor
cell
tumor
volum
growth
report
two
independ
experi
n
c
tumor
harvest
weigh
day
tumor
inocul
repres
tumor
photograph
shown
two
independ
experi
n
e
ten
day
immun
vlp
titer
neutral
antibodi
measur
human
respiratori
syncyti
viru
rsv
commonest
caus
agent
acut
low
respiratori
ill
infant
immunocompromis
adult
collin
crow
licens
vaccin
rsv
avail
sinc
develop
safe
effect
candid
challeng
hall
vaccin
candid
respiratori
syncyti
viru
rsv
report
schwarz
et
al
consist
e
colimad
vlp
assembl
matrix
matrix
protein
coencapsid
within
phage
vlp
fuse
ctermin
residu
sp
cterminu
protein
chimera
vaccin
administr
mice
use
two
dose
interv
stimul
memori
respons
lung
importantli
challeng
anim
show
reduc
lung
viral
titer
promis
approach
sinc
accessori
adjuv
requir
studi
jiao
et
al
consist
evalu
vlp
carri
matrix
protein
fusion
glycoprotein
f
vaccin
candid
respiratori
syncyti
viru
rsv
produc
vero
cell
mice
im
immun
vlp
singl
dose
inactiv
rsv
pfumous
firsv
dose
mgmous
im
vlp
present
posit
immunoreact
function
compar
rsv
virion
vitro
administ
vaccin
induc
polar
respons
effect
mucos
virusneutr
antibodi
tcell
respons
mucos
system
level
wherea
im
immun
induc
effect
respons
system
level
upon
challeng
rsv
immun
mice
show
increas
viral
clearanc
decreas
sign
enhanc
lung
patholog
fewer
eosinophil
compar
mice
immun
formalininactiv
rsv
firsv
administ
vlp
induc
respons
last
month
therefor
approach
promis
develop
effect
safe
mucos
vaccin
rsv
infect
although
product
mammalian
cell
costli
compar
system
eg
bacteria
yeast
plant
cell
fig
continu
sera
use
standard
microneutr
assay
n
two
independ
experi
f
g
ten
day
immun
vlp
mice
inject
cell
day
afterward
sacrif
measur
ha
restimul
splenocyt
supernat
n
two
independ
experi
f
vitro
cytotox
assay
use
target
cell
splenocyt
cfselabel
perform
quantif
dead
cell
use
cfse
cell
two
independ
experi
n
shown
g
h
tumor
cell
inocul
day
n
upon
tumor
detect
half
mice
vaccin
arrow
data
analyz
oneway
anova
tukey
multipl
comparison
test
dg
twoway
anova
bonferroni
posttest
c
valu
repres
mean
sem
p
p
taken
serradel
et
al
sever
acut
respiratori
syndrom
coronaviru
sarscov
first
emerg
infecti
agent
caus
sever
sometim
fatal
respiratori
diseas
human
fatal
rate
remark
neg
econom
social
impact
peiri
et
al
chimer
vlp
obtain
use
insect
cell
express
sar
spike
protein
influenza
protein
mice
immun
im
dose
sar
vlp
vaccin
without
aluminum
hydroxid
dose
sar
vlp
vaccin
boost
perform
day
sar
vlp
vaccin
dose
complet
protect
mice
im
administ
sar
vlp
vaccin
dose
without
adjuv
reduc
lung
viru
titer
detect
level
protect
mice
weight
loss
elicit
high
level
neutral
antibodi
sarscov
solubl
sar
protein
also
protect
im
administ
along
aluminum
hydroxid
sinc
vaccin
produc
procedur
follow
product
influenza
vlp
vaccin
success
evalu
phase
phase
ii
clinic
studi
author
propos
platform
facil
implement
allow
rapid
vaccin
product
case
sar
pandem
group
streptococcu
ga
caus
annual
death
deriv
rheumat
fever
rheumat
heart
diseas
poststreptococc
glomerulonephr
invas
infect
carapeti
et
al
riverahernandez
et
al
design
chimer
vlp
base
murin
polyomaviru
mupyv
protein
display
antigen
peptid
group
streptococcu
ga
epitop
insert
amino
acid
posit
singl
repeat
element
includ
glyser
linker
flank
chimer
protein
express
e
coli
assembl
vitro
vlp
fig
administ
mice
thrice
day
dose
studi
vlp
induc
signific
igg
iga
respons
thu
gener
system
mucos
respons
respect
interestingli
upon
challeng
ga
bacteri
colon
throat
significantli
lower
vlpimmun
mice
also
show
mild
protect
lethal
challeng
vs
surviv
neg
control
fig
improv
vaccin
could
compris
use
accessori
adjuv
dose
adjust
noroviru
nov
import
etiolog
agent
acut
gastroenter
infect
individu
age
children
especi
paula
et
al
plantmad
vlp
use
immun
norwalk
viru
highli
costattract
shown
low
immunogen
potenti
look
enhanc
efficaci
vaccin
approach
explor
vlp
base
nv
without
express
plant
n
benthamiana
appli
jackson
herbstkralovetz
use
immun
scheme
determin
effect
variou
adjuv
murabutid
mb
adjuv
target
nucleotidebind
oligomer
domaincontain
protein
receptor
gardiquimod
gard
agonist
cholera
toxin
ct
wellknown
mucos
adjuv
mice
immun
twice
interv
vlp
alon
supplement
one
follow
mb
level
gard
ct
mb
show
optim
adjuv
effect
coadminist
dose
base
magnitud
vlpspecif
igg
iga
product
serum
vlpspecif
iga
product
distal
mucos
site
vaccin
use
vlp
mb
induc
humor
respons
similar
magnitud
achiev
coadministr
vlp
ct
gard
im
immun
vlp
plu
alum
interestingli
term
induct
mucos
immun
respons
mb
group
equival
ct
gard
induc
compar
system
respons
achiev
parenter
vaccin
plu
alum
dri
powder
formul
gelvac
base
inert
situ
gell
polysaccharid
gelsit
obtain
alo
vera
assess
pig
nasal
immun
model
velasquez
et
al
author
compar
immunogen
dri
powder
vlp
formul
vs
equival
antigenadjuv
liquid
formul
purpos
test
anim
immun
twice
interv
one
follow
mgnari
gelvac
alon
gelvac
contain
vlp
gelvac
vlp
gardiquimod
gard
agonist
use
accessori
adjuv
parallel
liquid
formul
lack
gelvac
contain
amount
nv
vlp
test
powder
formul
without
vlp
similar
structur
dri
form
rehydr
simul
nasal
fluid
gelvac
powder
induc
higher
antibodi
respons
system
mucos
aerodigest
reproduct
tract
level
compar
liquid
formul
inclus
gard
increas
immunogen
dri
formul
posit
effect
record
liquid
formul
author
hypothes
test
formul
upon
situ
gelat
allow
vlp
stabil
end
prolong
presenc
mucos
surfac
overcom
mucociliari
clearanc
thu
extend
antigen
uptak
apc
nalt
research
group
subsequ
evalu
vlp
resembl
gi
noroviru
identifi
optim
dose
guinea
pig
pig
immun
twice
interv
springer
et
al
test
dose
rang
vlp
humor
respons
magnitud
follow
dosedepend
pattern
serum
vagin
wash
dose
allow
reach
maximum
antibodi
respons
neutral
potenti
assess
assay
base
estim
capac
vlp
bind
porcin
gastric
mucin
incub
sera
immun
anim
neutral
activ
gi
vlp
proven
nevertheless
challeng
assay
report
interest
outcom
accessori
adjuv
use
suggest
bival
vaccin
target
norovirus
could
produc
dri
powder
vaccin
offer
high
stabil
coldchain
free
vaccin
could
becom
realiti
bahamondezcana
cui
review
specif
topic
recent
interestingli
clinic
trial
norwalk
vlp
vaccin
genotyp
perform
elkamari
et
al
vaccin
produc
insect
cell
adjuv
monophosphoryl
lipid
mpl
agonist
deriv
detoxifi
salmonella
minnesota
lipopolysaccharid
mucoadher
agent
chitosan
healthi
subject
year
old
immun
twice
interv
studi
evalu
vlp
studi
evalu
dosag
vaccin
induc
seriou
advers
event
nasal
stuffi
discharg
sneez
frequent
side
effect
antivlp
igg
iga
level
increas
respect
dosag
level
fig
subject
receiv
either
dose
present
iga
antibodi
secret
cell
asc
measur
peripher
blood
mononuclear
cell
asc
express
molecul
associ
home
mucos
peripher
lymphoid
tissu
integrin
subset
express
exclus
mucos
home
molecul
also
detect
therefor
vaccin
consid
safe
highli
immunogen
could
progress
phase
ii
clinic
trial
polio
viru
pv
multipli
intestin
invad
central
nervou
system
caus
irrevers
paralysi
infect
peopl
present
need
subunit
vaccin
abl
confer
mucos
protect
without
use
attenu
strain
given
risk
revers
pathogen
form
bandyopadhyay
et
al
daniel
et
al
develop
plantmad
vaccin
pv
express
lettuc
vlp
base
chimer
protein
compris
protein
pv
cholera
toxin
b
subunit
assembl
nm
size
evidenc
mice
prime
sc
ipv
boost
three
time
mg
lyophil
tissu
squalen
andor
saponin
plu
andor
human
antimicrobi
peptid
adjuv
addit
respect
enhanc
antipv
iga
well
neutral
activ
seroposit
sabin
induc
upon
boost
plantmad
vlp
compar
treatment
base
ipv
singl
dose
boost
vlp
without
ipv
prime
consid
promis
result
sinc
popul
worldwid
receiv
ipv
singl
dose
thu
booster
coldchain
free
vaccin
might
use
aid
polio
erad
hepat
b
viru
infect
major
public
health
problem
worldwid
estim
popul
show
serolog
evid
current
past
infect
although
vaccin
avail
led
import
decreas
infect
new
vaccin
still
requir
fight
pathogen
group
head
pniewski
et
al
work
develop
plantmad
vaccin
hepat
b
formul
lettuc
tissu
express
hepat
b
viru
small
surfac
protein
shbsag
assembl
vlp
within
plant
cell
recent
studi
focus
assess
sever
scheme
determin
potenti
lowcost
vaccin
serv
boost
agent
combin
im
administr
convent
vaccin
produc
yeast
engerixb
im
prime
commerci
vaccin
follow
doubl
oral
boost
plantmad
vlp
compar
effici
standard
im
vaccin
boost
dose
ng
efficaci
enhanc
system
respons
fig
none
test
adjuv
improv
respons
vaccin
efficaci
plant
lysat
lower
intact
plant
cell
suggest
bioencapsul
shbsag
plant
cell
favor
vaccin
activ
requir
accessori
adjuv
fig
relev
studi
sinc
plantbas
platform
offer
low
product
cost
freezedri
plant
materi
stabl
room
temperatur
thu
formul
booster
vaccin
easili
perform
prepar
capsul
tablet
contain
plant
powder
hepat
e
gener
selflimit
acut
rare
fatal
diseas
treat
antivir
often
insuffici
unsaf
thu
develop
vaccin
hev
import
goal
nishiyama
et
al
niikura
et
al
report
product
insect
cell
chimer
vlp
compris
truncat
hepat
e
viru
aa
fuse
bcell
epitop
glycoprotein
herp
simplex
viru
chimer
vlp
show
morpholog
similar
matur
hev
virion
display
target
epitop
accord
immunoassay
mice
oral
immun
four
time
vlp
interv
chimer
vlp
induc
specif
intestin
igg
iga
insert
epitop
hevvlp
intestin
secret
author
propos
optim
dose
vlp
enhanc
signific
humor
respons
immunoprotect
assay
report
li
et
al
produc
vlp
resembl
hepat
e
viru
hev
express
insect
cell
hev
capsid
protein
gene
lack
amino
acid
ntermin
vaccin
administ
oral
cynomolgu
monkey
macaca
fasciculari
scheme
base
mg
vlp
dose
administ
day
subsequ
iv
hev
challeng
test
vaccin
induc
specif
serum
igm
igg
iga
respons
without
adjuv
upon
challeng
one
monkey
fulli
protect
anoth
one
infect
occur
develop
diseas
fecal
iga
detect
oral
immun
monkey
human
papillomaviru
hpv
sexual
transmit
viru
respons
develop
cervic
cancer
anal
cancer
head
throat
cancer
genit
area
wart
aksoy
et
al
insect
cellmad
vaccin
hpv
evalu
gerber
et
al
vaccin
base
vlp
assembl
protein
mice
immun
im
dose
vlp
oral
dose
vlp
alon
coadminist
cpg
dna
boost
dose
week
administ
vlp
coadminist
lt
induc
higher
serum
igg
titer
vlp
alon
immun
vlp
plu
lt
induc
higher
vagin
antivlp
igg
iga
antibodi
vlp
alon
plu
cpg
dna
similar
result
obtain
vlp
adjuv
enhanc
iga
respons
vlp
plu
lt
induc
posit
mesenter
lymphoprolif
respons
properti
characterist
associ
virusneutr
antibodi
specif
appear
unalt
test
adjuv
human
immunodefici
viru
hiv
pathogen
licens
vaccin
avail
genet
variabl
mechan
immun
evas
factor
hamper
vaccin
develop
rahman
robertguroff
poteet
et
al
report
hiv
vlp
compos
hiviiib
gag
hivbal
envelop
produc
hek
cell
vlp
coupl
vesivax
conjugat
adjuv
lipid
vesicl
calv
contain
one
follow
tolllikereceptor
tlr
ligand
dsrna
mpla
resiquimod
mice
immun
thrice
interv
vlp
dose
prime
boost
perform
subcheek
boost
vlp
coupl
ligand
dsrna
complex
calv
combin
vlp
calv
dsrna
vlp
induc
strongest
humor
respons
target
hiv
antigen
importantli
antibodi
clade
c
induc
respons
evidenc
igg
subclass
analysi
potent
neutral
antibodi
hiv
strain
also
gener
calv
dsrna
vlp
well
signific
increas
germin
center
bcell
follicular
cell
type
immun
scheme
exemplifi
mucos
vaccin
combin
boost
administ
inject
order
optim
induc
immun
profil
kang
et
al
gener
vlp
simian
immunodefici
viru
siv
compris
gag
env
protein
express
insect
cell
vlp
conjug
cholera
toxin
b
subunit
determin
immunogen
enhanc
subtransmucos
carrier
mice
immun
week
vlp
vlp
plu
ctb
ct
vlp
conjug
ctb
major
result
coadministr
vlp
ctb
induc
higher
level
antisiv
igg
iga
mucosa
saliva
vaginalwash
lung
intestin
higher
neutral
activ
compar
vlp
alon
conjug
ctb
vlp
also
enhanc
siv
vlpspecif
antibodi
sera
mucosa
similar
level
ctbconjug
vlp
induc
superior
cellular
respons
splenocyt
cytotoxictlymphocyt
activ
respect
vlpsctb
mixtur
along
enhanc
serum
level
indic
enhanc
cellular
immun
respons
alkadah
et
al
report
rotaviru
vaccin
produc
insect
cell
base
vlp
compos
bovin
rotaviru
author
test
effect
includ
mutant
version
heat
labil
enterotoxin
e
coli
immun
scheme
base
either
ir
rout
singl
dose
administ
vaccin
alon
induc
antigenspecif
secret
tcell
contrast
secret
tcell
migrat
mesenter
lymph
node
mln
detect
cervic
lymph
node
cln
spleen
inclus
improv
immunogen
term
activ
product
increas
secret
induc
antigenspecif
cln
spleen
mln
secret
tcell
unmodifi
ir
administ
vaccin
plu
induc
product
nonetheless
unlik
scheme
trigger
product
neutral
studi
perform
determin
compar
protect
potenti
vaccin
approach
binjawadagi
et
al
evalu
vaccin
porcin
reproduct
respiratori
syndrom
prr
use
insect
cellmad
vlp
contain
protein
whole
cell
lysat
mycobacterium
tuberculosi
tbwcl
coadminist
adjuv
vlp
administ
alon
entrap
plga
nanoparticl
averag
size
nm
immunoassay
confirm
presenc
protein
vlp
suggest
retent
antigen
determin
pig
immun
vlp
two
dose
interv
entrap
plga
nanoparticl
induc
anamnest
immun
respons
sinc
elev
igg
product
observ
challeng
vaccin
group
show
twolog
reduct
lung
viral
load
author
suggest
efficaci
improv
eg
includ
viral
structur
protein
produc
vlp
carri
heterodim
heterotetram
interact
complex
expect
resembl
nativ
virion
vlpsbase
vaccin
candid
infect
nervou
necrosi
viru
nnv
produc
express
recombin
orangespot
grouper
nnv
osgnnv
capsid
protein
e
coli
test
vaccin
evalu
orangespot
grouper
immun
twice
interv
immers
fish
bodi
weight
mg
vlp
lseawat
min
immers
intramuscular
inject
dose
fbw
vlp
per
fish
oral
dose
fbw
feed
day
food
contain
vlp
consumpt
bodi
weight
osgnnv
vlp
elicit
strong
humor
respons
immers
im
rout
induc
higher
humor
respons
oral
scheme
upon
challeng
rel
percent
surviv
valu
immers
inject
oral
immun
respect
type
vaccin
highli
promis
accessori
adjuv
requir
immun
immers
feed
practic
implement
aquacultur
addit
e
coliexpress
protein
cheaper
produc
compar
insect
mammalian
cellbas
product
crisci
et
al
report
vlpsbase
vaccin
candid
footandmouth
diseas
viru
fmdv
vaccin
consist
chimer
insect
cellmad
vlp
base
rabbit
hemorrhag
diseas
viru
rhdv
carri
tcell
epitop
protein
fmdv
vaccin
evalu
pig
immun
either
im
dose
administ
twice
interv
montanidetm
isa
adjuv
im
immun
chimer
vlp
activ
immatur
porcin
bone
marrowderiv
dendrit
cell
pobmdc
vitro
igg
iga
antibodi
rhdvvlp
induc
adjuv
im
immun
group
show
highest
humor
respons
adjuv
group
exhibit
highest
secret
cell
number
lymphoprolif
specif
tcell
respons
epitop
rhdvvlp
neutral
challeng
experi
conduct
citarasu
et
al
produc
vaccin
macrobrachium
rosenbergii
nodaviru
mrnv
caus
agent
white
tail
diseas
wtd
freshwat
giant
prawn
macrobrachium
rosenbergii
vaccin
compris
insect
cellmad
vlp
assembl
mrnv
capsid
protein
obtain
vlp
use
oral
immun
larva
purpos
anim
fed
vlpsupplement
feed
day
mrnv
ad
g
feed
lead
daili
intak
ng
vlp
test
period
either
day
vaccin
period
prawn
oral
challeng
virul
mrnv
surviv
rate
achiev
day
postvaccin
respect
wherea
nonvaccin
group
mortal
pathogen
load
estim
pcr
decreas
day
postvaccin
respect
vaccin
induc
express
mramp
believ
involv
innat
immun
respons
mrnv
infect
data
induct
adapt
immun
respons
present
vlp
stand
promis
agent
develop
subunit
vaccin
thank
high
immunogen
stabil
versatil
safeti
term
toxic
clear
vlp
constitut
one
safest
nanoparticul
system
conform
protein
contrast
metal
polymer
nanoparticl
depend
size
shape
dose
could
lead
toxic
effect
overcom
challeng
develop
mucos
vaccin
doubt
driven
vlpsbase
approach
substanti
advanc
last
year
despit
major
vlpsbase
vaccin
develop
thu
far
evalu
parenter
immun
scheme
report
summar
present
chapter
indic
substanti
potenti
achiev
develop
mucos
vlp
real
possibl
becom
agent
fight
relev
diseas
human
anim
case
influenza
vaccin
indic
remark
nich
mucos
vlp
vaccin
candid
effect
case
possess
higher
efficaci
parenter
vaccin
scheme
clear
use
chimer
vlp
carri
accessori
adjuv
target
tlr
effect
approach
enhanc
vaccin
efficaci
key
perspect
identifi
topic
compris
develop
vlpsbase
vaccin
target
specif
receptor
mucos
tissu
increas
vaccin
efficaci
transport
mcell
critic
step
induct
immun
mucos
rout
target
cell
specif
ligand
increas
uptak
antigen
increas
access
uptak
antigen
present
cell
first
step
induct
robust
adapt
immun
respons
purpos
mcelltarget
peptid
ligand
describ
kim
et
al
concept
proven
vaccin
porcin
epidem
diarrhea
viru
coe
antigen
fuse
exhibit
higher
immunogen
term
induc
system
mucos
immun
respons
huy
et
al
best
knowledg
approach
appli
vlpsbase
vaccin
anoth
goal
could
expand
use
nontox
subunit
cholera
toxin
ctb
b
subunit
e
coli
heat
labil
enterotoxin
ltb
subunit
bind
gangliosid
present
membran
epitheli
cell
allow
antigen
transport
submucosa
although
sever
promis
vlpsbase
vaccin
candid
found
literatur
vaccin
produc
insect
mammalian
cell
expens
product
platform
expand
use
lowcost
platform
plant
relev
perspect
technolog
led
influenza
vaccin
candid
current
clinic
trial
administ
parenter
rout
pillet
et
al
anoth
attract
approach
one
recent
report
serradel
et
al
expect
lead
oral
vaccin
candid
sever
infecti
diseas
addit
fact
vaccin
approach
result
effect
cancer
model
make
vaccin
highli
attract
field
cancer
immunotherapi
given
promis
vaccin
cancer
administ
parenter
rout
therefor
innov
oral
cancer
vaccin
use
approach
envisag
detail
explor
innov
immun
rout
point
deserv
consider
vlpsbase
vaccin
sublingu
immun
recent
highlight
attract
allow
induc
robust
immun
respons
bahcecil
et
al
therefor
expand
evalu
vplsbase
vaccin
sl
rout
open
new
possibl
address
vaccinolog
challeng
instanc
group
head
kweon
work
evalu
sl
vaccin
group
streptococcu
base
vlp
assembl
structur
protein
murin
polyomaviru
mupyv
produc
e
coli
seth
et
al
vlp
advantag
agent
vaccin
develop
lead
doubt
advanc
clinic
fight
infecti
noncommunic
diseas
interest
vlpsbase
vaccin
candid
emerg
pathogen
zika
viru
yang
et
al
nipah
viru
walpita
et
al
chikungunya
viru
et
al
ebola
viru
rosalesmendoza
et
al
develop
howev
vaccin
candid
mainli
evalu
parenter
immun
scheme
evalu
scheme
base
mucos
immun
remain
relev
pend
goal
know
mucos
vaccin
could
lead
higher
efficaci
scheme
base
parenter
administr
use
primeboost
scheme
also
studi
systemat
way
achiev
better
immun
profil
ie
optim
immun
respons
system
mucos
level
anoth
innov
expect
follow
year
relat
appli
computerbas
model
method
ensur
proper
antigen
spatial
conform
especi
chimer
vlp
conform
epitop
critic
vaccin
efficaci
liljeroo
et
al
gener
sophist
vlp
contain
antigen
arrang
multimer
array
carrier
surfac
well
differ
immunostimul
compon
envisag
